Valuation: AbbVie

Market Cap 455B 395B 367B 338B 637B 43,418B 649B 4,343B 1,700B 21,564B 1,708B 1,670B 72,517B P/E 2026 *
32.4x
P/E 2027 * 23.5x
Enterprise Value 511B 444B 412B 380B 716B 48,809B 729B 4,882B 1,912B 24,241B 1,920B 1,878B 81,521B EV / Sales 2026 *
7.6x
EV / Sales 2027 * 6.9x
Free-Float
95.71%
Yield 2026 *
2.67%
Yield 2027 * 2.81%
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 455B
-4.55%-2.61%+51.95%+151.91% 1,030B
-3.66%-1.33%+52.95%+46.62% 617B
+0.86%+0.31%+38.55%+31.63% 350B
+0.57%+0.46%+35.34%+39.98% 299B
+0.25%+0.70%+12.67%+14.06% 265B
-0.39%+2.51%+4.50%-39.82% 225B
0.00%+4.34%+28.63%+64.00% 209B
-1.09%+0.32%+14.40%+70.80% 163B
-0.95%-0.40%+4.62%-30.94% 142B
Average -0.67%+4.53%+27.07%+38.69% 366.65B
Weighted average by Cap. -0.61%+4.84%+37.44%+67.73%

Financials

2026 *2027 *
Net sales 67.27B 58.43B 54.26B 50.04B 94.25B 6,422B 95.96B 642B 251B 3,189B 253B 247B 10,726B 72.86B 63.29B 58.77B 54.2B 102B 6,956B 104B 696B 272B 3,455B 274B 268B 11,617B
Net income 14.42B 12.53B 11.63B 10.73B 20.21B 1,377B 20.57B 138B 53.92B 684B 54.15B 52.97B 2,299B 19.25B 16.72B 15.53B 14.32B 26.97B 1,838B 27.46B 184B 71.97B 913B 72.28B 70.7B 3,069B
Net Debt 56.47B 49.05B 45.55B 42B 79.12B 5,391B 80.55B 539B 211B 2,677B 212B 207B 9,004B 48.27B 41.93B 38.93B 35.91B 67.64B 4,608B 68.86B 461B 180B 2,289B 181B 177B 7,697B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
AA